The risk of hearing impairment in MHD patients with abnormally high expression of FGF23 and D-serine was 16.54 and 15.22 times higher than in MHD patients with lower FGF23 and D-serine levels, respectively. The gene discussed is FGF23; the disease is Hearing impairment.